City

Tianjin (2)

Ann Arbor (1)

Chicago (1)

Guangzhou (1)

Hershey (1)

Iowa City (1)

New Brunswick (1)

Condition

Advanced Kidney Cancer (4)

Clear Cell Renal Cell Carcinoma (1)

Kidney Cancer (1)

Overall Status

Recruiting (2)

Active, not recruiting (1)

Withdrawn (1)

Sign in for free

Phase

phase 2 (3)

phase 1/phase 2 (1)

Sponsor

Tianjin Medical University Second Hospital (2)

Ajjai Alva, MD (1)

Fuda Cancer Hospital, Guangzhou (1)

Collaborator

AstraZeneca (1)

Benhealth Biopharmaceutical (Shenzhen) Co., Ltd. (1)

Big Ten Cancer Research Consortium (1)

Intervention

activated cik and cd3-muc1 bispecific antibody in treating kidney cancer (1)

cryotherapy (1)

durvalumab (1)

guadecitabine (1)

pembrolizumab plus lenvatinib (1)

tislelizumab lenvatinib (1)

Study Documents

Intervention Type

drug (3)

biological (1)

procedure (1)

Funder Type

Other (4)

Study Type

Interventional (4)

advanced kidney cancer

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Advanced Kidney Cancer Trial in Tianjin (Tislelizumab Lenvatinib)

Recruiting

Advanced Kidney Cancer

Tislelizumab Lenvatinib

Tianjin, Tianjin, China

Changyi Quan

Aug 4, 2022

Advanced Kidney Cancer Trial in Tianjin (Pembrolizumab plus Lenvatinib)

Recruiting

Advanced Kidney Cancer

Pembrolizumab plus Lenvatinib

Tianjin, Tianjin, China

Changyi Quan

Aug 4, 2022

Advanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell Carcinoma Trial in United States (Guadecitabine, Durvalumab)

Active, not recruiting

Advanced Kidney Cancer
+2 more

Chicago, Illinois
+4 more

Feb 16, 2022

Advanced Kidney Cancer Trial in Guangzhou (Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer,

Withdrawn

Advanced Kidney Cancer

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Kidney Cancer
cryotherapy

Guangzhou, Guangdong, China

Institutional Review Board of Guangzhou Fuda Cancer Hospital

Oct 13, 2020